Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SPR994 in Healthy Volunteers
NCT03395249Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Oct 2017
- Primary completion
- Aug 2018
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tebipenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (4 arms), sponsored by Spero Therapeutics. Primary endpoints: Adverse Events, Concomitant Medications and 8 more. Started Oct 2017; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT03395249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395249.